Immuron Ltd has released a press release.
NMRC Reports Results for Campylobacter Clinical Study
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Immuron
- Trading Halt
- Immuron Plans Phase 2 Trial for IMM-529 following FDA review
- Appendix 4E and Preliminary Final Report
- Immuron Travelan record sales globally, Australia and USA
- IMM-529 pre-IND FDA filing
Later from Immuron
- Immuron Announces Travelan Clinical Trial Update
- Immuron Travelan continued strong sales growth
- IMC and Calmino to treat Irritable Bowel Syndrome (IBS)
- Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS)
- Immuron Travelan highest sales in history
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron